Kang Li
About Kang Li
Kang Li is the Head of Biologics at BeiGene (Beijing) Co., Ltd, with extensive experience in oncology research and preclinical drug development.
Current Title and Company
Kang Li is the Head of Biologics at BeiGene (Beijing) Co., Ltd, located in Zhong-Guan-Cun Life Science Park, Changping District, Beijing, China. With his extensive background in biologics and pharmaceuticals, Kang brings a wealth of expertise to his role at BeiGene.
Previous Professional Experience
Kang Li has accumulated extensive experience in the pharmaceutical industry. At Crown Bioscience, Inc., he served as the Executive Director in Taicang, Jiangsu, for one year from 2010 to 2011. Prior to that, he was a Senior Principal Scientist at Pfizer from 2007 to 2010. He spent six years at Tanox/Genentech, working as Scientist II to Senior Scientist and Project Leader in the R&D Department from 2001 to 2007. Kang also has academic experience from his time at UT Southwestern Medical Center at Dallas, where he served as a Postdoctoral Researcher and Research Assistant Professor from 1990 to 2000.
Educational Background
Kang Li holds an MBA in Business Management from The University of Dallas, which he earned between 1997 and 2000. He completed his Ph.D. in Biochemistry and Molecular Biology at Emory University from 1985 to 1990. Additionally, he earned an M.S. in Cell Biology from Wuhan University from 1979 to 1982 and a B.S. in Biology from Henan Normal University from 1974 to 1977.
Scientific Expertise
Kang Li possesses strong scientific expertise in various areas including cancer stem cell signaling, apoptosis, energy metabolism, and mast cell-mediated inflammation and autoimmune diseases. His profound understanding extends to oncology target identification, antibody drug discovery, and key technologies for preclinical drug development.
Managerial and Project Leadership
In his managerial roles, Kang Li has led preclinical R&D research, including his positions as Head of Biologics at BeiGene and Crown Bioscience. At Pfizer, he directed both antibody and small molecule projects during his three-year tenure as a Senior Principal Scientist. He also led multiple projects as a program leader at Tanox for seven years. Kang emphasizes sound decision-making, efficient operations, and detail-oriented execution in his leadership approach.